Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Abraham J Matar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Pancreas Transplantation, Lymphoproliferative Disorders, Postoperative Complications, Graft Survival. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Chronic immunosuppression following pancreas transplantation carries significant risk, including posttransplant lymphoproliferative disease (PTLD). We sought to define the incidence, risk factors, and long‐term outcomes of PTLD following pancreas transplantation at a single center.
Methods
All adult pancreas transplants between February 1, 1983 and December 31, 2023 at the University of Minnesota were reviewed, including pancreas transplant alone (PTA), simultaneous pancreas–kidney transplants (SPK), and pancreas after kidney transplants (PAK).
Results
Among 2353 transplants, 110 cases of PTLD were identified, with an overall incidence of 4.8%. 17.3% were diagnosed within 1 year of transplant, 32.7% were diagnosed within 5 years, and 74 (67.3%) were diagnosed after 5 years. The overall 30‐year incidence of PTLD did not differ by transplant type—7.4% for PTA, 14.2% for SPK, and 19.4% for PAK ( p = 0.3). In multivariable analyses, older age and Epstein‐Barr virus seronegativity were risk factors for PTLD, and PTLD was a risk factor for patient death. PTLD‐specific mortality was 32.7%, although recipients with PTLD had similar median posttransplant survival compared to those without PTLD (14.9 year vs. 15.6 year, p = 0.9).
Conclusions
PTLD following pancreas transplantation is associated with significant mortality. Although the incidence of PTLD has decreased over time, a high index of suspicion for PTLD following PTx should remain in EBV‐negative recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Abraham J Matar, Erik B Finger, Jessica Fisher, Arthur J Matas
Zitieren
APA
Matar, A. J., Finger, E. B., Maakaron, J., Minja, E., Ramanathan, K., Humphreville, V., Rao, J. S., Fisher, J., Sutherland, D. E. R., Matas, A. J., & Kandaswamy, R. (2024). Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.15386
Vancouver
Matar AJ, Finger EB, Maakaron J, Minja E, Ramanathan K, Humphreville V, et al. Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience. Clinical Transplantation. 2024. doi:10.1111/ctr.15386
BibTeX
@article{Matar2024,
author = {Matar, Abraham J and Finger, Erik B and Maakaron, Joseph and Minja, Emmanuel and Ramanathan, Karthik and Humphreville, Vanessa and Rao, Joseph S and Fisher, Jessica and Sutherland, David E R and Matas, Arthur J and Kandaswamy, Raja},
title = {Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15386}
}
EUVIMED